Updated Efficacy and Safety Data from the Phase 2 NP28761 Study of Alectinib in ALK-Positive Non-Small-Cell Lung Cancer

被引：8

作者：

Camidge, D. Ross ^{[1
]}

Gadgeel, Shirish ^{[2
]}

Ou, Sai-Hong ^{[3
]}

Gandhi, Leena ^{[4
]}

Riely, Gregory ^{[5
]}

Cetnar, Jeremy ^{[6
]}

West, Howard ^{[7
]}

Socinski, Mark ^{[8
]}

Chiappori, Alberto ^{[9
]}

Mekhail, Tarek ^{[10
]}

Chao, Bo ^{[11
]}

Borghaei, Hossein ^{[12
]}

Gold, Kathryn ^{[13
]}

Bordogna, Walter ^{[14
]}

Balas, Bogdana ^{[14
]}

Noe, Johannes ^{[14
]}

Golding, Sophie ^{[14
]}

Zeaiter, Ali ^{[14
]}

Shaw, Alice ^{[15
]}

机构：

[1] Univ Colorado, Aurora, CO USA

[2] Wayne State Univ, Karmanos Canc Inst, Detroit, MI USA

[3] Univ Calif Irvine, Sch Med, Orange, CA 92668 USA

[4] Dana Farber Canc Inst, Boston, MA 02115 USA

[5] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA

[6] Oregon Hlth & Sci Univ, Portland, OR 97201 USA

[7] Swedish Canc Inst, Seattle, WA USA

[8] Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA

[9] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA

[10] Florida Hosp, Canc Inst, Orlando, FL USA

[11] Ohio State Univ, Columbus, OH 43210 USA

[12] Fox Chase Canc Ctr, 7701 Burholme Ave, Philadelphia, PA 19111 USA

[13] Univ Texas MD Anderson Canc Ctr, Thorac Med Oncol, Houston, TX 77030 USA

[14] F Hoffmann La Roche, Basel, Switzerland

[15] Massachusetts Gen Hosp, Boston, MA 02114 USA

来源：

JOURNAL OF THORACIC ONCOLOGY | 2017年 / 12卷 / 01期

关键词：

Alectinib; NSCLC; US; ALK-inhibitor;

D O I：

10.1016/j.jtho.2016.11.426

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

MA07.02

引用

页码：S378 / S378

页数：1

共 50 条

[1] Updated Efficacy/Safety Data From the Phase 2 NP28761 Study of Alectinib in ALK plus NSCLC
Shaw, Alice
West, Howard
Socinski, Mark A.
Ou, Ignatius
Gandhi, Leena
Gadgeel, Shirish
Belani, Chandra P.
Shirai, Keisuke
Bazhenova, Lyudmila
Santos, Edgardo
Riely, Gregory J.
Chiappori, Alberto
Cetnar, Jeremy
Mekhail, Tarek
Chao, Bo
Borghaei, Hossein
Gold, Kathryn A.
Johannsdottir, Hrefna
Ruf, Thorsten
Boisserie, Frederic
Henschel, Volkmar
Zeaiter, Ali
Camidge, Ross
JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S237 - S238
[2] Pooled overall survival and safety data from the pivotal phase II studies (NP28673 and NP28761) of alectinib in ALK-positive non-small-cell lung cancer
Ou, Sai-Hong Ignatius
Gadgeel, Shirish M.
Barlesi, Fabrice
Yang, James Chih-Hsin
De Petris, Luigi
Kim, Dong-Wan
Govindan, Ramaswamy
Dingemans, Anne-Marie
Crino, Lucio
Lena, Herve
Popat, Sanjay
Ahn, Jin Seok
Dansin, Eric
Mitry, Emmanuel
Mueller, Barbara
Bordogna, Walter
Balas, Bogdana
Morcos, Peter N.
Shaw, Alice T.
LUNG CANCER, 2020, 139 : 22 - 27
[3] Pooled Systemic Efficacy and Safety Data from the Pivotal Phase II Studies (NP28673 and NP28761) of Alectinib in ALK-positive Non-Small Cell Lung Cancer
Yang, James Chih-Hsin
Ou, Sai-Hong Ignatius
De Petris, Luigi
Gadgeel, Shirish
Gandhi, Leena
Kim, Dong-Wan
Barlesi, Fabrice
Govindan, Ramaswamy
Dingemans, Anne-Marie C.
Crino, Lucio
Lena, Nerve
Popat, Sanjay
Ahn, Jin Seok
Dansin, Eric
Golding, Sophie
Bordogna, Walter
Batas, Bogdana
Morcos, Peter N.
Zeaiter, Ali
Shaw, Alice T.
JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (10) : 1552 - 1560
[4] Pooled Efficacy and Safety Data from Two Phase II Studies (NP28673 and NP28761) of Alectinib in ALK plus Non-Small-Cell Lung Cancer (NSCLC)
Yang, James Chih-Hsin
Ou, Sai-Hong
De Petris, Luigi
Gadgeel, Shirish
Gandhi, Leena
Kim, Dong-Wan
Barlesi, Fabrice
Govindan, Ramaswamy
Dingemans, Anne-Marie
Crino, Lucio
Lena, Herve
Popat, Sanjay
Ahn, Jin Seok
Dansin, Eric
Golding, Sophie
Bordogna, Walter
Balas, Bogdana
Morcos, Peter N.
Zeaiter, Ali
Shaw, Alice
JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1170 - S1171
[5] Pooled overall survival and safety data from the pivotal phase II studies (NP28673 and NP28761) of alectinib in ALK-positive non-small cell lung cancer (NSCLC).
Ou, Sai-Hong Ignatius
Gandhi, Leena
Gadgeel, Shirish M.
Barlesi, Fabrice
Yang, James Chih-Hsin
De Petris, Luigi
Kim, Dong-Wan
Govindan, Ramaswamy
Dingemans, Anne-Marie C.
Crino, Lucio
Herve, Lena
Popat, Sanjay
Ahn, Jin Seok
Dansin, Eric
Zeaiter, Ali Hassan
Mueller, Barbara
Johannsdottir, Hrefna
Balas, Bogdana
Morcos, Peter N.
Shaw, Alice
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[6] Efficacy and safety study with alectinib in advanced ALK-positive non-small-cell lung cancer
Fernandez Madrigal, Laura
Garcia Samblas, Victoria
Amor Urbano, Maria
Inoriza, Angel
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[7] Alectinib for ALK-positive non-small-cell lung cancer
Rossi, Antonio
EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2016, 9 (08) : 1005 - 1013
[8] Pooled mutation analysis for the NP28673 and NP28761 studies of alectinib in ALK plus non-small-cell lung cancer (NSCLC).
Puig, Oscar
Yang, James Chih-Hsin
Ou, Sai-Hong Ignatius
Chiappori, Alberto
Chao, Bo H.
Belani, Chandra Prakash
Spira, Alexander I.
Bearz, Alessandra
Duruisseaux, Michael
Allard, John
Birzele, Fabian
Boisserie, Frederic
Lonngren, Ulrika
Bordogna, Walter
Klass, Daniel M.
Newman, Aaron M.
Zeaiter, Ali Hassan
Shaw, Alice Tsang
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[9] Alectinib for treatment of ALK-positive non-small-cell lung cancer
Avrillon, Virginie
Perol, Maurice
FUTURE ONCOLOGY, 2017, 13 (04) : 321 - 335
[10] Alectinib in resected ALK-positive non-small-cell lung cancer
Gourmet, Anais
Ferrari, Victoria
BULLETIN DU CANCER, 2024, 111 (10) : 905 - 906

← 1 2 3 4 5 →